Agios Pharmaceuticals

Agios Pharmaceutical Inc.
Company type	Public
Traded as	Nasdaq: AGIO; Russell 1000 Component
Industry	Pharmaceuticals
Founded	2008; 16 years ago
Headquarters	Cambridge, Massachusetts, United States
Key people	Brian Goff (CEO)
Revenue	$118 Million(2019)
Number of employees	536
Website	agios.com
	Footnotes / references; Foundation

Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias.^[3] The company was founded in 2008 (or 2007)^[4] by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts.^[2]^[5] The company tendered an initial public offering in July 2013.^[6]^{: Table 1}

History

In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios.^[4]

In May 2016, the company announced it would launch partnership with Celgene,^[7] developing metabolic immuno-oncology therapies and licensing AG-221 as well as AG-881 to Celgene, potentially garnering Agios $120 million in drug licensing payments.^[8]

In April 2017, the company raised $250 million in a new stock offering in anticipation of approval for its first cancer drug, enasidenib, by the US Food and Drug Administration.^[9]

In December 2017, the company filed a New Drug Application with the US FDA for ivosidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an IDH1 mutation.^[10]

In November 2019, Agios announced an underwritten public offering of 8,250,000 shares of common stock at a price of $31.00 per share which would result in approximately $256 million aggregate gross proceeds.^[11]

In April 2022, the FDA approved mitapivat as first disease-modifying therapy for hemolytic anemia in adults with pyruvate kinase deficiency.^[12]

Corporate governance

As of August 2022^[update], Agios' CEO is Brian Goff.^[13]

Agios was established as a private company and converted to a public company with its initial public offering in July 2013 and subsequent listing on NASDAQ.^[4]^[6]

References

^ "Agios Reports Fourth Quarter and Full Year 2019 Financial Results – Agios Pharmaceuticals, Inc".
^ ^a ^b Pfeffer, Cary G. (2012). "The biotechnology sector". In Burns, Lawton R. (ed.). The Business of Healthcare Innovation (Google eBook). Cambridge, United Kingdom: Cambridge University Press. pp. 224, 228. ISBN 9781107024977.
^ "About Us".
^ ^a ^b ^c Pollack, Andrew (February 5, 2012). "Sloan-Kettering Chief Is Accused of Taking Research". The New York Times.
^ "AGIOS PHARMACEUTICALS, INC". EDGAR. Form 10-K. U.S. Securities and Exchange Commission. March 18, 2014. Commission File Number:001-36014.
^ ^a ^b Huggett, Brady (December 2013). "Burning Bright". Nat. Biotechnol. Vol. 31, no. 12. pp. 1068–71.
^ "Celgene, Agios, Launch $1B+ Metabolic Immuno-oncology Alliance - GEN News Highlights - GEN". GEN. 17 May 2016.
^ Williams, Sean (3 June 2016). "3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016". The Moteley Fool. Retrieved 13 July 2018.
^ "Agios bags $250M in offering as cancer drug speeds toward approval". Boston Business Journal. April 19, 2017.
^ Agios Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2017.
^ "Agios Announces Pricing of $256 Million Public Offering of Common Stock". www.nasdaq.com. Retrieved 2020-03-12.
^ "Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency". Agios. Cambridge, MA. 17 February 2022. Retrieved 24 April 2023.
^ "Agios Appoints Brian Goff as Chief Executive Officer".

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

[1] "Agios Reports Fourth Quarter and Full Year 2019 Financial Results – Agios Pharmaceuticals, Inc".

[burns2012-2] Pfeffer, Cary G. (2012). "The biotechnology sector". In Burns, Lawton R. (ed.). The Business of Healthcare Innovation (Google eBook). Cambridge, United Kingdom: Cambridge University Press. pp. 224, 228. ISBN 9781107024977.

[3] "About Us".

[pollack2012-4] Pollack, Andrew (February 5, 2012). "Sloan-Kettering Chief Is Accused of Taking Research". The New York Times.

[10k2013-5] "AGIOS PHARMACEUTICALS, INC". EDGAR. Form 10-K. U.S. Securities and Exchange Commission. March 18, 2014. Commission File Number:001-36014.

[huggett2013-6] Huggett, Brady (December 2013). "Burning Bright". Nat. Biotechnol. Vol. 31, no. 12. pp. 1068–71.

[7] "Celgene, Agios, Launch $1B+ Metabolic Immuno-oncology Alliance - GEN News Highlights - GEN". GEN. 17 May 2016.

[8] Williams, Sean (3 June 2016). "3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016". The Moteley Fool. Retrieved 13 July 2018.

[:0-9] "Agios bags $250M in offering as cancer drug speeds toward approval". Boston Business Journal. April 19, 2017.

[10] Agios Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2017.

[11] "Agios Announces Pricing of $256 Million Public Offering of Common Stock". www.nasdaq.com. Retrieved 2020-03-12.

[12] "Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency". Agios. Cambridge, MA. 17 February 2022. Retrieved 24 April 2023.

[13] "Agios Appoints Brian Goff as Chief Executive Officer".

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]